Searchable abstracts of presentations at key conferences in endocrinology

ea0029p692 | Diabetes | ICEECE2012

Therapy with analogous of glp 1 and basal insulin in patients with diabetes mellitus type 2. Our experience.

Perez Rodriguez J. , Morales Portillo C. , Garcia Garcia C. , Fernandez Pena I. , Hernando Jimenez V. , Serrano Olmedo I. , De la Cuesta Mayor C. , Sendon Perez

Objectives: Evaluate the impact of the therapy with GLP-1 analogues (exenatide) toguether with basal insulin in glycemic control and weight of patients with type 2 diabetes mellitus poorly controlled.Materials and methods: We analyzed 37 patients with type 2 diabetes with poor glycemic control and obesity, treatment with exenatide and basal insulin. As pre-treatment 56.7% of our patients were with basal insulin, 10.8% with insulin mixtures and 32.4% with...

ea0083erco2 | Endocrine-related Cancer | EYES2022

Ablation of Znrf3 & Trp53 induces metastatic adrenocortical carcinoma in mice

J. Wilmouth JR , J. Olabe , L. Landwehr , L. Pucheu , D. Dufour , F. Roucher-Boulez , C. Lucas-Rodrigues , D. Garcia-Garcia , C. Damon-Soubeyrand , M. Kroiss , M. Fassnacht , A. Lefrancois-Martinez , A. Martinez , P. Val

Background: Adrenocortical carcinoma (ACC) is an aggressive cancer originating from steroidogenic cells within the adrenal cortex. Unfortunately, half of patients present with metastatic spread upon initial diagnosis, and there is no curative therapy for advanced disease. Genomic analysis has identified that the most aggressive subgroup of ACC patients have overlapping alterations in the WNT/β-catenin pathway and the p53/RB signaling pathway.Objecti...

ea0073yi8 | Young Investigator Awards | ECE2021

Metformin and simvastatin in combination: drugs repositioning to impair high-grade astrocytomas progression

Fuentes-Fayos Antonio C. , Garcia Garcia Miguel , Jiménez-Vacas Juan M , Martin-Colom Julia , Doval-Rosa Carlos , Blanco-Acevedo Cristobal , Gahete Ortiz Manuel , Castaño Justo P. , Juan Solivera , Luque Raul M.

Astrocytomas are a subtype of malignant gliomas characterized by rapid growth and high diffusion through the brain. Based on the agresiveness features, they are stratified from low grades (I and II) to high grades (HGAs; III and IV), being grade-IV [glioblastoma multiforme (GBM)] the most aggressive and one of the most common malignant cancers in the brain, with an overall survival from diagnosis of ~14 months. Current standard therapies to treat HGAs are not efficient and the...